Related coverage linked through entity extraction aliases.
Apr 20, 2026
Kyverna Therapeutics reports positive long-term follow-up results for its CAR-T therapy miv-cel in generalized myasthenia gravis, with plans to submit a biologics license application in the first half of 2026. The company has $279.3 million in cash providing runway into 2028 to fund launch and Phase 3 trials.
Mar 28, 2026
Autolus Therapeutics reported $74.3 million in 2025 revenue during its first commercial year, while facing a -265% gross margin. The company aims to achieve positive margins by 2026 through scaling production and expanding into autoimmune diseases with promising early lupus trial results. The broader CAR-T therapy market is projected to reach $9.85 billion in the US by 2033.
Mar 14, 2026
Immunic Inc presented additional data from its Phase 2 CALIPER trial at the ACTRIMS Forum, showing Vidofludimus calcium reduced both acute and chronic brain lesions in progressive multiple sclerosis patients and demonstrated clinical evidence of reduced EBV reactivation.
Mar 06, 2026
A Phase 1 trial of azer-cel, a CAR T-cell therapy using donor T-cells to target B-cells, is recruiting patients with progressive multiple sclerosis at eight U.S. sites. Separately, multiple randomized trials are comparing hematopoietic stem cell transplantation against high-efficacy disease-modifying therapies.
